Tracy Staton

Biography for Tracy Staton

Tracy Staton, Senior Editor

Tracy Staton is the editor of FiercePharma and FiercePharmaMarketing. She has been a freelance writer for eight years, but before that served as editor of the Dallas Business Journal, editor of Texas Business magazine, and a senior editor at American Way, the inflight magazine of American Airlines. She is based in Vermont, and can be reached at tracy@fiercemarkets.com or find her on LinkedIn.

Articles by Tracy Staton

Express Scripts rolls out value-based pricing for cancer meds

Express Scripts will put its money behind a new value-based reimbursement model next year, using comparative data and indication-specific pricing to favor "clinically superior" meds. The pharmacy benefits manager will roll out the approach in cancer first, with anti-inflammatory meds close behind.

Pfizer close to record-breaking Allergan deal at up to $380 per share: Bloomberg

Pfizer and Allergan are close to striking a deal that would be the biggest of 2015 by far--and the biggest healthcare deal ever, Bloomberg reports. The price: $370 to $380 per share, or almost $150 billion.

Millennial men lead the charge in seeking info from pharma marketing

Men have pharma needs, too. Traditional pharma marketing strategies target women, following common marketing wisdom that women control or influence the vast majority of household purchases, up to 80% or more depending on which study you read. But new research from ID Media points to men taking a more active role in healthcare. 

Allergan demands CEO slot for Saunders as condition for Pfizer buyout: Forbes

If Pfizer does make a friendly deal for Allergan, CEO Ian Read will be giving up his seat at the helm. That's the word from sources at Pfizer, who told Forbes' John LaMattina that current negotiations depend on Allergan CEO Brent Saunders taking charge at the combined company.

Bristol-Myers nabs FDA priority review for new Opdivo use in kidney cancer

The FDA put Bristol-Myers Squibb's immuno-oncology drug Opdivo on its priority review fast track for a new use in kidney cancer. It would be yet another new indication for Opdivo, which was first approved for melanoma last year and now boasts two indications in lung cancer. 

Pharma faces 'challenging and prolonged' reforms in China, with pricing power at risk

Big Pharma has already seen sales in China slow, thanks in part to stepped-up competition from local drugmakers. Healthcare reform there is also taking its toll. But Fitch Ratings says pharma's troubles in China are only beginning.

AstraZeneca stokes Tagrisso's blockbuster hopes with $12,750-per-month sticker

AstraZeneca unveiled its pricing plan for the new targeted lung cancer pill Tagrisso that won early FDA approval Friday: $12,750 per month, or $153,000 for a full year of treatment. That's on par with other targeted cancer pills, including the company's own Iressa, a spokeswoman tells Reuters.

J&J undercuts Celgene's Pomalyst with $135K-per-year Darzalex price

Johnson & Johnson's new multiple myeloma treatment Darzalex (daratumumab) scored a speedy FDA approval, entering a market that's already crowded with last-ditch treatments. But the company is hoping an impressive response rate will help the new med knock aside Celgene's Pomalyst and Amgen's Kyprolis in the battle for market share.

Can Valeant win without big price hikes? Early Addyi scripts aren't a good sign

Addyi, the female libido drug developed by Sprout Pharmaceuticals, was rejected twice by the FDA and abandoned by Boehringer Ingelheim before a public lobbying campaign helped push it onto the market last month. Valeant dropped $1 billion to buy Sprout soon after the drug's FDA approval. That bet isn't working out as planned, at least so far.

Stepped-up Nucynta sales push starts paying off for Depomed

Depomed's relaunch of the Nucynta franchise--purchased earlier this year from Johnson & Johnson--is off to a running start, the company said last week with its Q3 earnings announcement. And it expects that momentum to carry it all the way to blockbuster land.